Base de dados : MEDLINE
Pesquisa : D03.066.515.375 [Categoria DeCS]
Referências encontradas : 544 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 55 ir para página                         

  1 / 544 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28424313
[Au] Autor:Lopez-Luna J; Al-Jubouri Q; Al-Nuaimy W; Sneddon LU
[Ad] Endereço:Department of Evolution, Ecology and Behaviour, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK jlopez@liverpool.ac.uk.
[Ti] Título:Reduction in activity by noxious chemical stimulation is ameliorated by immersion in analgesic drugs in zebrafish.
[So] Source:J Exp Biol;220(Pt 8):1451-1458, 2017 Apr 15.
[Is] ISSN:1477-9145
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Research has recently demonstrated that larval zebrafish show similar molecular responses to nociception to those of adults. Our study explored whether unprotected larval zebrafish exhibited altered behaviour after exposure to noxious chemicals and screened a range of analgesic drugs to determine their efficacy to reduce these responses. This approach aimed to validate larval zebrafish as a reliable replacement for adults as well as providing a high-throughput means of analysing behavioural responses. Zebrafish at 5 days post-fertilization were exposed to known noxious stimuli: acetic acid (0.01%, 0.1% and 0.25%) and citric acid (0.1%, 1% and 5%). The behavioural response of each was recorded and analysed using novel tracking software that measures time spent active in 25 larvae at one time. Subsequently, the efficacy of aspirin, lidocaine, morphine and flunixin as analgesics after exposure to 0.1% acetic acid was tested. Larvae exposed to 0.1% and 0.25% acetic acid spent less time active, whereas those exposed to 0.01% acetic acid and 0.1-5% citric acid showed an increase in swimming activity. Administration of 2.5 mg l aspirin, 5 mg l lidocaine and 48 mg l morphine prevented the behavioural changes induced by acetic acid. These results suggest that larvae respond to a noxious challenge in a similar way to adult zebrafish and other vertebrates and that the effect of nociception on activity can be ameliorated by using analgesics. Therefore, adopting larval zebrafish could represent a direct replacement of a protected adult fish with a non-protected form in pain- and nociception-related research.
[Mh] Termos MeSH primário: Ácido Acético/farmacologia
Analgésicos/farmacologia
Comportamento Animal/efeitos dos fármacos
Ácido Cítrico/farmacologia
Nociceptividade/efeitos dos fármacos
Noxas/farmacologia
Peixe-Zebra/fisiologia
[Mh] Termos MeSH secundário: Animais
Aspirina/farmacologia
Clonixino/análogos & derivados
Clonixino/farmacologia
Avaliação Pré-Clínica de Medicamentos/métodos
Larva/efeitos dos fármacos
Larva/fisiologia
Lidocaína/farmacologia
Morfina/farmacologia
Estimulação Química
Natação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Noxae); 2968PHW8QP (Citric Acid); 356IB1O400 (flunixin); 76I7G6D29C (Morphine); 98PI200987 (Lidocaine); Q40Q9N063P (Acetic Acid); R16CO5Y76E (Aspirin); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170616
[Lr] Data última revisão:
170616
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.1242/jeb.146969


  2 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28358605
[Au] Autor:Ratliff CM; Zaffarano BA
[Ti] Título:Therapeutic Use of Regional Limb Perfusion in a Chicken.
[So] Source:J Avian Med Surg;31(1):29-32, 2017 Mar.
[Is] ISSN:1082-6742
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 2-year-old, 3.8-kg male Rhode Island red rooster was examined for lameness and progressive swelling of the right foot of several month's duration. Radiographs of the right foot demonstrated soft tissue swelling and a smoothly marginated periosteal reaction evident of inflammation affecting the bones. Results of a complete blood count showed a moderate leukocytosis and an elevated total protein concentration. Systemic antibiotic and anti-inflammatory therapy was started, but the bird had not improved at recheck examination. After intravenous catheterization of the medial metatarsal vein and placing a tourniquet at the femoral-tibiotarsal joint of the right leg, regional limb perfusion with amikacin and flunixin meglumine was performed. Dimensions of both feet were measured with digital calipers, and surface temperatures of the feet were measured with an infrared thermometer. The rooster had improved activity level with decrease in lameness and measurable decrease in swelling of the right foot. Regional limb perfusion with intravenous antibiotics and nonsteroidal anti-inflammatory drugs is a viable treatment modality in avian species for suspected distal limb infection and cellulitis. This technique has potential valuable implications for a variety of avian species. Fluid support should be provided if using nephrotoxic drugs.
[Mh] Termos MeSH primário: Amicacina/uso terapêutico
Galinhas
Injeções Intravenosas/veterinária
Doenças das Aves Domésticas/tratamento farmacológico
[Mh] Termos MeSH secundário: Amicacina/administração & dosagem
Animais
Antibacterianos/uso terapêutico
Anti-Inflamatórios não Esteroides/administração & dosagem
Anti-Inflamatórios não Esteroides/uso terapêutico
Clonixino/administração & dosagem
Clonixino/análogos & derivados
Clonixino/uso terapêutico
Membro Posterior
Injeções Intravenosas/métodos
Masculino
Torniquetes
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents, Non-Steroidal); 84319SGC3C (Amikacin); 8Y3JK0JW3U (flunixin meglumine); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170622
[Lr] Data última revisão:
170622
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170331
[St] Status:MEDLINE
[do] DOI:10.1647/2015-149


  3 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28086988
[Au] Autor:Braun U; Malbon A; Kochan M; Riond B; Janett F; Iten C; Dennler M
[Ad] Endereço:Department of Farm Animals, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. ubraun@vetclinics.uzh.ch.
[Ti] Título:Computed tomographic findings and treatment of a bull with pituitary gland abscess.
[So] Source:Acta Vet Scand;59(1):8, 2017 Jan 13.
[Is] ISSN:1751-0147
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In cattle, the prognosis of brain abscess is unfavourable and treatment is therefore not recommended. To the knowledge of the authors, there has been no report of successful treatment of a brain abscess in cattle.This report describes the clinical, computed tomographic and postmortem findings in a Holstein-Friesian bull with a hypophyseal abscess. CASE REPORT: The main clinical findings were generalised ataxia, ptyalism, prolapse of the tongue, dropped jaw, dysphagia, head tilt and unilateral ptosis. Cerebrospinal fluid evaluation revealed 2437 leukocytes/µl and severe pleocytosis. CT examination of the head showed a cavitary lesion consistent with an abscess in the hypophysis. Treatment consisted of gentamicin and flunixin meglumine for 3 days and amoxicillin for 40 days. The neurological signs resolved within 8 days of the start of treatment. The bull was slaughtered 11 months later because of infertility, and a postmortem examination was carried out. Histologically, a mild chronic non suppurative meningoencephalitis restricted to the ventral diencephalon was diagnosed. In addition, there was mild to moderate multifocal chronic lymphoplasmacytic hypophysitis with mild multifocal fibrosis. CONCLUSIONS: This case report stresses the significance of CT in confirming the clinical and laboratory diagnosis of central nervous system disorders in cattle and for localising brain lesions. Treatment of the brain abscess resulted, with respect to the central nervous disorder, in a successful outcome and was encouraging considering that most cases have an unfavourable prognosis.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Abscesso Encefálico/veterinária
Doenças dos Bovinos/diagnóstico por imagem
Doenças dos Bovinos/tratamento farmacológico
Hipófise/diagnóstico por imagem
Hipófise/patologia
Tomografia Computadorizada por Raios X/veterinária
[Mh] Termos MeSH secundário: Amoxicilina/uso terapêutico
Animais
Abscesso Encefálico/tratamento farmacológico
Abscesso Encefálico/microbiologia
Abscesso Encefálico/patologia
Bovinos
Doenças dos Bovinos/microbiologia
Doenças dos Bovinos/patologia
Clonixino/análogos & derivados
Clonixino/uso terapêutico
Gentamicinas/uso terapêutico
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Gentamicins); 804826J2HU (Amoxicillin); 8Y3JK0JW3U (flunixin meglumine); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170115
[St] Status:MEDLINE
[do] DOI:10.1186/s13028-017-0276-1


  4 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28058945
[Au] Autor:Sidhu PK; Gehring R; Mzyk DA; Marmulak T; Tell LA; Baynes RE; Vickroy TW; Riviere JE
[Ti] Título:Avoiding violative flunixin meglumine residues in cattle and swine.
[So] Source:J Am Vet Med Assoc;250(2):182-189, 2017 Jan 15.
[Is] ISSN:1943-569X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacocinética
Bovinos
Clonixino/análogos & derivados
Resíduos de Drogas/farmacocinética
Suínos
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/química
Clonixino/química
Clonixino/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 8Y3JK0JW3U (flunixin meglumine); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.2460/javma.250.2.182


  5 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28042099
[Au] Autor:Pineros I; Slowing K; Serrano DR; de Pablo E; Ballesteros MP
[Ad] Endereço:Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad Complutense of Madrid, Plaza Ramon y Cajal s/n, Madrid 28040, Spain.
[Ti] Título:Analgesic and anti-inflammatory controlled-released injectable microemulsion: Pseudo-ternary phase diagrams, in vitro, ex vivo and in vivo evaluation.
[So] Source:Eur J Pharm Sci;101:220-227, 2017 Apr 01.
[Is] ISSN:1879-0720
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Development of analgesic and anti-inflammatory controlled-released injectable microemulsions utilising lysine clonixinate (LC) as model drug and generally regarded as safe (GRAS) excipients. METHODS: Different microemulsions were optimised through pseudo-ternary phase diagrams and characterised measuring droplet size, viscosity, ex vivo haemolytic activity and in vitro drug release. The anti-inflammatory and analgesic activity was tested in mice (Hot plate test) and rats (Carrageenan-induced paw edema test) respectively and their activity was compared to an aqueous solution of LC salt. RESULTS: The aqueous solution showed a faster and shorter response whereas the optimised microemulsion increased significantly (p<0.01) the potency and duration of the analgesic and anti-inflammatory activity after deep intramuscular injection. The droplet size and the viscosity were key factors to control the drug release from the systems and enhance the effect of the formulations. CONCLUSIONS: The microemulsion consisting of Labrafil®/Lauroglycol®/Polysorbate 80/water with LC (56.25/18.75/15/10, w/w) could be a promising formulation after buccal surgery due to its ability to control the drug release and significantly achieve greater analgesic and anti-inflammatory effect over 24h.
[Mh] Termos MeSH primário: Analgésicos/administração & dosagem
Anti-Inflamatórios/administração & dosagem
Preparações de Ação Retardada/administração & dosagem
Emulsões/administração & dosagem
[Mh] Termos MeSH secundário: Analgésicos/química
Animais
Anti-Inflamatórios/química
Química Farmacêutica/métodos
Clonixino/administração & dosagem
Clonixino/análogos & derivados
Clonixino/química
Preparações de Ação Retardada/química
Sistemas de Liberação de Medicamentos/métodos
Liberação Controlada de Fármacos
Emulsões/química
Excipientes/química
Seres Humanos
Injeções/métodos
Injeções Intramusculares/métodos
Lisina/administração & dosagem
Lisina/análogos & derivados
Lisina/química
Masculino
Camundongos
Tamanho da Partícula
Polissorbatos/química
Ratos
Ratos Wistar
Viscosidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Inflammatory Agents); 0 (Delayed-Action Preparations); 0 (Emulsions); 0 (Excipients); 0 (Polysorbates); 06PW4M190R (lysine clonixinate); K3Z4F929H6 (Lysine); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170103
[St] Status:MEDLINE


  6 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27865498
[Au] Autor:Newby NC; Leslie KE; Dingwell HD; Kelton DF; Weary DM; Neuder L; Millman ST; Duffield TF
[Ad] Endereço:Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1.
[Ti] Título:The effects of periparturient administration of flunixin meglumine on the health and production of dairy cattle.
[So] Source:J Dairy Sci;100(1):582-587, 2017 Jan.
[Is] ISSN:1525-3198
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Research on the assessment and management of pain in cows following difficult or assisted calving is still limited, especially on the effects of analgesics intended to mitigate this pain. The purpose of this study was to assess the effects of flunixin meglumine on the health and production of Holstein cows after calving. In total, 34 flunixin-treated and 38 placebo-treated animals were enrolled in a precalving treatment trial. A total of 633 animals given flunixin and 632 animals administered a placebo were enrolled in a postcalving treatment trial. In both cases, animals were randomly assigned to treatment, and researchers were blind to treatment condition until after analysis. A total of 1,265 animal records were analyzed for milk production for the first 14d in milk and health outcomes for the first 30d in milk. Animals treated with flunixin meglumine before calving had a significantly increased risk of stillbirth. Animals treated immediately after calving had increased odds of having a retained placenta and, in turn, increased risk of a high temperature, decreased milk production, and an increased risk of developing metritis. The administration of flunixin meglumine within 24h of parturition is not recommended in dairy cattle.
[Mh] Termos MeSH primário: Clonixino/análogos & derivados
Leite
Parto
[Mh] Termos MeSH secundário: Animais
Bovinos
Doenças dos Bovinos/tratamento farmacológico
Clonixino/administração & dosagem
Feminino
Lactação/efeitos dos fármacos
Placenta Retida
Gravidez
Natimorto/veterinária
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
8Y3JK0JW3U (flunixin meglumine); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161121
[St] Status:MEDLINE


  7 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27958751
[Au] Autor:Shelver WL; Schneider MJ; Smith DJ
[Ad] Endereço:Biosciences Research Laboratory, Agricultural Research Service, U.S. Department of Agriculture , 1605 Albrecht Boulevard North, Fargo, North Dakota 58102, United States.
[Ti] Título:Distribution of Flunixin Residues in Muscles of Dairy Cattle Dosed with Lipopolysaccharide or Saline and Treated with Flunixin by Intravenous or Intramuscular Injection.
[So] Source:J Agric Food Chem;64(51):9697-9701, 2016 Dec 28.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Twenty dairy cows received flunixin meglumine at 2.2 mg/kg bw, administered once daily by either the intravenous (IV) or intramuscular (IM) route for three consecutive days with either intravenous normal saline (NS) or lipopolysaccharide (LPS) providing a balanced design with five animals per group. Cows were sacrificed after a 4 day withdrawal period, and 13 muscle types were collected and assayed for flunixin by LC-MS/MS. After elimination of sample outliers, the main effects of route of administration (IV or IM), treatment (NS or LPS), and tissue type significantly (P < 0.05) affected flunixin residues, with no interaction (P > 0.05). Intramuscular (nonlabel) flunixin administration produced greater (P < 0.05) flunixin residues in muscle than the IV (label) administration, whereas LPS resulted in lower flunixin levels. Differences among the tissue levels indicate it is necessary to specify the tissue to be used for any monitoring of drug levels for consumer protection.
[Mh] Termos MeSH primário: Doenças dos Bovinos/tratamento farmacológico
Clonixino/análogos & derivados
Resíduos de Drogas/farmacocinética
Inflamação/veterinária
Músculo Esquelético/química
Drogas Veterinárias/farmacocinética
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/administração & dosagem
Anti-Inflamatórios/análise
Anti-Inflamatórios/farmacocinética
Bovinos
Clonixino/administração & dosagem
Clonixino/análise
Clonixino/farmacocinética
Resíduos de Drogas/análise
Inflamação/tratamento farmacológico
Injeções Intramusculares
Injeções Intravenosas
Lipopolissacarídeos/efeitos adversos
Cloreto de Sódio/administração & dosagem
Cloreto de Sódio/farmacocinética
Drogas Veterinárias/administração & dosagem
Drogas Veterinárias/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Lipopolysaccharides); 0 (Veterinary Drugs); 356IB1O400 (flunixin); 451W47IQ8X (Sodium Chloride); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161214
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.6b04792


  8 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27731498
[Au] Autor:Burkett BN; Thomason JM; Hurdle HM; Wills RW; Fontenot RL
[Ad] Endereço:Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi.
[Ti] Título:Effects of Firocoxib, Flunixin Meglumine, and Phenylbutazone on Platelet Function and Thromboxane Synthesis in Healthy Horses.
[So] Source:Vet Surg;45(8):1087-1094, 2016 Nov.
[Is] ISSN:1532-950X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Determine the effects of nonsteroidal anti-inflammatory drugs (NSAID) on platelet function and thromboxane synthesis immediately after drug administration and following 5 days of NSAID administration in healthy horses. STUDY DESIGN: Randomized cross-over study. ANIMALS: Healthy adult horses (n=9; 6 geldings and 3 mares). METHODS: Horses received either flunixin meglumine (1.1 mg/kg IV every 12 hours), phenylbutazone (2.2 mg/kg IV every 12 hours), or firocoxib (loading dose of 0.27 mg/kg IV on day 1, then 0.09 mg/kg IV every 24 hours for 4 days) for a total of 5 days. Blood samples were collected prior to drug administration (day 0), 1 hour after initial NSAID administration (day 1), and then 1 hour post-NSAID administration on day 5. Platelet function was assessed using turbidimetric aggregometry and a platelet function analyzer. Serum thromboxane B concentrations were determined by commercial ELISA kit. A minimum 14 day washout period occurred between trials. RESULTS: At 1 hour and 5 days postadministration of firocoxib, flunixin meglumine, or phenylbutazone, there was no significant effect on platelet aggregation or function using turbidimetric aggregometry or a platelet function analyzer. There was, however, a significant decrease in thromboxane synthesis at 1 hour and 5 days postadministration of flunixin meglumine and phenylbutazone that was not seen with firocoxib. CONCLUSION: Preoperative administration of flunixin meglumine, phenylbutazone, or firocoxib should not inhibit platelet function based on our model. The clinical implications of decreased thromboxane B synthesis following flunixin meglumine and phenylbutazone administration are undetermined.
[Mh] Termos MeSH primário: 4-Butirolactona/análogos & derivados
Anti-Inflamatórios não Esteroides/administração & dosagem
Plaquetas/efeitos dos fármacos
Clonixino/análogos & derivados
Cavalos/metabolismo
Fenilbutazona/administração & dosagem
Sulfonas/administração & dosagem
Tromboxanos/metabolismo
[Mh] Termos MeSH secundário: 4-Butirolactona/administração & dosagem
4-Butirolactona/metabolismo
Animais
Anti-Inflamatórios não Esteroides/metabolismo
Clonixino/administração & dosagem
Clonixino/metabolismo
Estudos Cross-Over
Feminino
Masculino
Fenilbutazona/metabolismo
Sulfonas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Sulfones); 0 (Thromboxanes); 8Y3JK0JW3U (flunixin meglumine); GN5P7K3T8S (Phenylbutazone); OL659KIY4X (4-Butyrolactone); V7DXN0M42R (Clonixin); Y6V2W4S4WT (firocoxib)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161013
[St] Status:MEDLINE
[do] DOI:10.1111/vsu.12567


  9 / 544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27227502
[Au] Autor:Kissell LW; Brinson PD; Gehring R; Tell LA; Wetzlich SE; Baynes RE; Riviere JE; Smith GW
[Ti] Título:Pharmacokinetics and tissue elimination of flunixin in veal calves.
[So] Source:Am J Vet Res;77(6):634-40, 2016 Jun.
[Is] ISSN:1943-5681
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE To describe plasma pharmacokinetic parameters and tissue elimination of flunixin in veal calves. ANIMALS 20 unweaned Holstein calves between 3 and 6 weeks old. PROCEDURES Each calf received flunixin (2.2 mg/kg, IV, q 24 h) for 3 days. Blood samples were collected from all calves before the first dose and at predetermined times after the first and last doses. Beginning 24 hours after injection of the last dose, 4 calves were euthanized each day for 5 days. Plasma and tissue samples were analyzed by ultraperformance liquid chromatography. Pharmacokinetic parameters were calculated by compartmental and noncompartmental methods. RESULTS Mean ± SD plasma flunixin elimination half-life, residence time, and clearance were 1.32 ± 0.94 hours, 12.54 ± 10.96 hours, and 64.6 ± 40.7 mL/h/kg, respectively. Mean hepatic and muscle flunixin concentrations decreased to below FDA-established tolerance limits (0.125 and 0.025 µg/mL, respectively) for adult cattle by 3 and 2 days, respectively, after injection of the last dose of flunixin. Detectable flunixin concentrations were present in both the liver and muscle for at least 5 days after injection of the last dose. CONCLUSIONS AND CLINICAL RELEVANCE The labeled slaughter withdrawal interval for flunixin in adult cattle is 4 days. Because administration of flunixin to veal calves represents extralabel drug use, any detectable flunixin concentrations in edible tissues are considered a violation. Results indicated that a slaughter withdrawal interval of several weeks may be necessary to ensure that violative tissue residues of flunixin are not detected in veal calves treated with that drug.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacocinética
Bovinos/sangue
Clonixino/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/sangue
Anti-Inflamatórios não Esteroides/química
Anti-Inflamatórios não Esteroides/metabolismo
Área Sob a Curva
Clonixino/sangue
Clonixino/química
Clonixino/metabolismo
Clonixino/farmacocinética
Resíduos de Drogas
Meia-Vida
Fígado/química
Músculo Esquelético/química
Músculo Esquelético/metabolismo
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 356IB1O400 (flunixin); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170127
[Lr] Data última revisão:
170127
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160527
[St] Status:MEDLINE
[do] DOI:10.2460/ajvr.77.6.634


  10 / 544 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27121728
[Au] Autor:Kleinhenz MD; Van Engen NK; Gorden PJ; KuKanich B; Rajewski SM; Walsh P; Coetzee JF
[Ad] Endereço:Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA.
[Ti] Título:The pharmacokinetics of transdermal flunixin meglumine in Holstein calves.
[So] Source:J Vet Pharmacol Ther;39(6):612-615, 2016 Dec.
[Is] ISSN:1365-2885
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study describes the pharmacokinetics of topical and intravenous (IV) flunixin meglumine in Holstein calves. Eight male Holsteins calves, aged 6 to 8 weeks, were administered flunixin at a dose of 2.2 mg/kg intravenously. Following a 10-day washout period, calves were dosed with flunixin at 3.33 mg/kg topically (transdermal). Blood samples were collected at predetermined times from 0 to 48 h for the intravenous portions and 0 to 72 h following topical dosing. Plasma drug concentrations were determined using liquid chromatography with mass spectroscopy. Pharmacokinetic analysis was completed using noncompartmental methods. The mean bioavailability of topical flunixin was calculated to be 48%. The mean AUC for flunixin was determined to be 13.9 h × ug/mL for IV administration and 10.1 h × ug/mL for topical administration. The mean half-life for topical flunixin was 6.42 h and 4.99 h for the intravenous route. The C following topical application of flunixin was 1.17 µg/mL. The time to maximum concentration was 2.14 h. Mean residence time (MRT) following IV injection was 4.38 h and 8.36 h after topical administration. In conclusion, flunixin when administered as a topical preparation is rapidly absorbed and has longer half-life compared to IV administration.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacocinética
Bovinos/sangue
Clonixino/análogos & derivados
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Anti-Inflamatórios não Esteroides/administração & dosagem
Anti-Inflamatórios não Esteroides/sangue
Área Sob a Curva
Clonixino/administração & dosagem
Clonixino/sangue
Clonixino/farmacocinética
Estudos Cross-Over
Feminino
Meia-Vida
Injeções Intravenosas
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 8Y3JK0JW3U (flunixin meglumine); V7DXN0M42R (Clonixin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160429
[St] Status:MEDLINE
[do] DOI:10.1111/jvp.12314



página 1 de 55 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde